Cytarabine, Daunorubicin, and Midostaurin induction therapy for acute myeloid leukemia (AML)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search



Regimen in use at

Regimen

FDA-recommended dose
Study Evidence Comparator Comparative Efficacy
Stone et al. 2017 (RATIFY) Phase III (E-RT) 7+3d (intermediate-dose) Superior OS

Chemotherapy

Supportive medications

  • Hydroxyurea (Hydrea) (no dosage specified) was allowed to be used for up to 5 days before the start of therapy while waiting for results of FLT3 mutation testing

21-day course; retreatment with a second course was allowed if day 21 bone marrow biopsy showed residual AML.

Subsequent treatment

References

  1. RATIFY: Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017 Aug 3;377(5):454-464. Epub 2017 Jun 23. link to original article link to PMC article contains verified protocol PubMed